Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis

European Journal of Health Economics

Volumn 18, Issue 4, 2017, Pages 405-415

  Haukaas, Fredrik Salvesen ^a,b   Arnesen, Trude Margrete ^a   Winje, Brita Askeland ^a   Aas, Eline ^b  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

CEA; Cost effectiveness analysis; Economic evaluation; EVPI; Expected value of perfect information; IGRA; Immigrants; Interferon gamma release assay; Latent tuberculosis; Norway; Screening; TST; Tuberculin skin test; Tuberculosis

Indexed keywords

ALGORITHM; ARTICLE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; IMMIGRANT; INCIDENCE; INFORMATION; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; NORWAY; PRIORITY JOURNAL; SCREENING; SENSITIVITY ANALYSIS; SHARED DECISION MAKING; COST BENEFIT ANALYSIS; DECISION TREE; ECONOMICS; MIGRANT; PROCEDURES; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; TUBERCULIN TEST; TUBERCULOSIS;

TUBERCULOSTATIC AGENT;

ALGORITHMS; ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; DECISION TREES; EMIGRANTS AND IMMIGRANTS; HEALTH CARE COSTS; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; NORWAY; RISK ASSESSMENT; TUBERCULIN TEST; TUBERCULOSIS;

EID: 84960391089     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-016-0779-0     Document Type: Article

References (34)

1. Merck: Tuberculosis (TB). http://www.merckmanuals.com/professional/infectious_diseases/mycobacteria/tuberculosis_tb.html. (2009). Accessed 7 November 2013
2. World Health Organization: Global tuberculosis report 2015. WHO http://www.who.int/tb/publications/global_report/en/ (2016). Accessed 13 January 2016
3. Dye, C., Scheele, S., Dolin, P., Pathania, V., Raviglione, M. C., for the W. H. O. G. S., & Monitoring Project. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA. 282(7), 677–686 (1999)
4. Dagnew, A., Hussein, J., Abebe, M., Zewdie, M., Mihret, A., Bedru, A., Aseffa, A.: Diagnosis of latent tuberculosis infection in healthy young adults in a country with high tuberculosis burden and BCG vaccination at birth. BMC Res Notes 5(1), 415 (2012)
5. Norwegian Institute of Public Health: Guide on tuberculosis. http://www.fhi.no/eway/default.aspx?pid=239&trg=Main_6157&Main_6157=7139:0:25,5500 (2013). Accessed 7 November 2013
6. Lin, P.L., Flynn, J.L.: Understanding latent tuberculosis: a moving target. J. Immunol. 185(1), 15–22 (2010)
7. Arnesen, T.M., Eide, K.Å., Norheim, G., Mengshoel, A.T., Sandbu, S., Winje, B.: Tuberculosis in Norway 2013—with treatment results for 2012. Norwegian Institute of Public Health. Oslo, Norway (2014)
8. Norwegian Institute of Public Health: Countries with high occurrence of tuberculosis. http://www.fhi.no/eway/default.aspx?pid=240&trg=Content_6671&Main_6664=6894:0:25,7555:1:0:0:::0:0&MainContent_6894=6671:0:25,7570:1:0:0:::0:0&List_6673=6674:0:25,7574:1:0:0:::0:0&Content_6671=6683:105433::1:6682:1:::0:0 (2014). Accessed 27 August 2014
9. Regulations on tuberculosis control. https://lovdata.no/dokument/SF/forskrift/2009-02-13-205?q=forskrift+om+tuberkulosekontroll (2009). Accessed 7 July 2015
10. Norwegian Institute of Public Health: Simplified tuberculosis control. http://www.fhi.no/artikler/?id=110976 (2014). Accessed 2 September 2014
11. Diel, R., Loddenkemper, R., Nienhaus, A.: Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest J 142(1), 63–75 (2012)
12. Nienhaus, A., Schablon, A., Costa, J.T., Diel, R.: Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv Res 11, 247 (2011)
13. Campbell, J.R., Sasitharan, T., Marra, F.: A systematic review of studies evaluating the cost utility of screening high-risk populations for latent tuberculosis infection. Appl Health Econ Health Policy. 13(4), 325–340 (2015)
14. Haukaas, F. S.: Screening immigrants for latent tuberculosis: a cost-effectiveness analysis in a Norwegian setting. Master’s thesis, University of Oslo, Oslo. http://urn.nb.no/URN:NBN:no-44714 (2014). Accessed 7 July 2015
15. ®TB Gold with tuberculin skin test. BMC Infect Dis 8(1), 1–10 (2008)
16. Harstad, I., Heldal, E., Steinshamn, S., Garasen, H., Jacobsen, G.: Tuberculosis screening and follow-up of asylum seekers in Norway: a cohort study. BMC Public Health 9(1), 141 (2009)
17. Olsen, A.I.M., Andersen, H.E., Aßmus, J., Djupvik, J.A., Gran, G., Skaug, K., Mørkve, O.: Management of latent tuberculous infection in Norway in 2009: a descriptive cross-sectional study. Public Health Action 3(2), 166–171 (2013)
18. Briggs, A., Claxton, K., Sculpher, M.: Decision modelling for health economic evaluation. Oxford University Press, New York (2006)
19. Wiker, H., Mustafa, T., Bjune, G., Harboe, M.: Evidence for waning of latency in a cohort study of tuberculosis. BMC Infect. Dis. 10(1), 37 (2010)
20. The Norwegian Directorate of Health. Economic evaluation of health technologies—a guide: The Norwegian Directorate of Health. https://helsedirektoratet.no/Lists/Publikasjoner/Attachments/624/Okonomisk-evaluering-av-helsetiltak-IS-1985.pdf (2012). Accessed 11 July 2015
21. Regulations on expenses for outpatient services. http://lovdata.no/dokument/LTI/forskrift/2013-12-12-1503 (2013). Accessed 24 April 2014
22. Statistics Norway: Salary for employees in the health trusts. http://www.ssb.no/arbeid-og-lonn/statistikker/lonnstasyk (2013). Accessed 30 January 2014
23. Norwegian Medical Association: Normaltariff for fastleger og legevakt 2013–2014. http://normaltariffen.legeforeningen.no/pdf/Fastlegetariff_2013.pdf (2013). Accessed 7 July 2014
24. Regulations on coverage of laboratory expenses. http://lovdata.no/dokument/LTI/forskrift/2013-12-17-1562 (2013). Accessed 24 April 2014
25. Norwegian Medicines Agency: Legemiddelsøk. http://www.legemiddelverket.no/Legemiddelsoek/Sider/default.aspx (2014). Accessed 17 March 2014
26. The Norwegian Directorate of Health: Innsatsstyrt finansiering 2013. http://www.helsedirektoratet.no/publikasjoner/innsatsstyrt-finansiering-2013/Publikasjoner/IS-2041_web.pdf (2012). Accessed 7 March 2014
27. Barton, G.R., Briggs, A.H., Fenwick, E.A.L.: Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health 11(5), 886–897 (2008)
28. Oxlade, O., Pinto, M., Trajman, A., Menzies, D.: How methodologic differences affect results of economic analyses: a systematic review of interferon gamma release assays for the diagnosis of LTBI. PLoS One 8(3), e56044 (2013)
29. Ena, J., Valls, V.: Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin. Infect. Dis. 40(5): 670–676 (2005). http://cid.oxfordjournals.org/content/40/5/670.full.pdf
30. Rennie, T. W., Bothamley, G. H., Engova, D., Bates, I. P.: Patient choice promotes adherence in preventive treatment for latent tuberculosis. Eur. Respir. J. 30(4): 728–735 (2007). http://www.ncbi.nlm.nih.gov/pubmed/17626113
31. Spyridis, N. P., Spyridis, P. G., Gelesme, A., Sypsa, V., Valianatou, M., et al.: The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin. Infect. Dis. 45(6): 715–722 (2007). http://www.ncbi.nlm.nih.gov/pubmed/17712755
32. Pareek, M., Watson, J.P., Ormerod, L.P., Kon, O.M., Woltmann, G., White, P.J., Lalvani, A.: Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis 11(6), 435–444 (2011)
33. Erkens, C.G.M., Dinmohamed, A.G., Kamphorst, M., Toumanian, S., van Nispen-Dobrescu, R., Alink, M., Oudshoorn, N., Mensen, M., van den Hof, S., Borgdorff, M., Verver, S.: Added value of interferon-gamma release assays in screening for tuberculous infection in the Netherlands. Int. J. Tuberc. Lung Dis. 18(4), 413–420 (2014)
34. Mulder, C.: Tuberculosis control among immigrants. In: Mulder, C. (ed) Factulteit der Geneeskunde (2013)